Remed Co

Remed Co Net Margin

The Net Profit Margin of Remed Co (302550.KQ) as of Nov 19, 2026 is 2.15 %. In the previous year, Net Profit Margin was 28.07 % — a change of -92.35% (lower).

Net Margin

2.15 %

YoY

-92.35%

Last updated:

Net Profit Margin of Remed Co is 2025 2.15 % . Net Profit Margin of Remed Co was 2024 28.07 % . It decreases by -92.35% lower compared to the previous year.

Remed Co's net margin stands at 2.1%, down from 3.7% several years earlier.

The Remed Co Net Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Margin
Date
Net Margin
Jan 1, 2018
-92.21 KRW
Jan 1, 2019
23.52 KRW
Jan 1, 2020
-11.02 KRW
Jan 1, 2021
3.73 KRW
Jan 1, 2022
18.72 KRW
Jan 1, 2023
4.30 KRW
Jan 1, 2024
28.07 KRW
Jan 1, 2025
2.15 KRW
The Remed Co Net Margin history
YEARNet MarginYoY
2.15 %-92.35%
28.07 %+552.61%
4.30 %-77.03%
18.72 %+402.62%
3.73 %-133.79%
-11.02 %-146.87%
23.52 %-125.51%
-92.21 %-15,983.09%
0.58 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Remed Co Stock analysis

What does Remed Co do? REMED Co., Ltd. generates revenue through the manufacturing and sale of medical equipment, including transcranial magnetic stimulation (TMS) therapy machines, pain therapy machines, and biosignal and monitoring machines. Pain therapy machines encompass electromagnetic stimulation machines, extracorporeal shockwave therapy machines, and high intensity laser therapy machines. Biosignal and monitoring machines include patient monitors, fetal monitors, and electrocardiogram (ECG/EKG) machines. The company distributes these products domestically and internationally, targeting healthcare providers and medical facilities that require specialized therapeutic and monitoring solutions. The firm's product portfolio focuses on advanced medical devices for neurological and pain management, as well as patient monitoring. Transcranial magnetic stimulation (TMS) therapy machines are used for neurological treatments, while pain therapy machines address chronic pain conditions. Biosignal and monitoring machines support critical patient care, with electrocardiogram (ECG/EKG) machines being a key component. These products are sold to hospitals, clinics, and medical centers across domestic and overseas markets. REMED Co., Ltd. serves healthcare institutions that require specialized equipment for diagnosis, treatment, and monitoring. The domestic market includes hospitals and clinics in Daejeon, while overseas markets extend to international healthcare providers. The company’s revenue streams are derived from direct sales of its medical equipment, with no mention of additional services or licensing agreements in the business description. Remed Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Remed Co stock

Net Profit Margin of Remed Co is 2.15 % in 2025.

Net Profit Margin of Remed Co changed from 28.07 % to 2.15 %, representing a -92.35% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Net Profit Margin Remed Co since 2006 – with annual values, charts, and detailed analysis.

Net Margin measures the percentage of revenue that becomes net profit after all expenses. It is the ultimate measure of a company's profitability.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Profit Margin's Remed Co with sector peers and the industry average to assess whether it is attractive.

To evaluate Net Profit Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Net Profit Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Remed Co

All Key Metrics — Remed Co